ASH Annual Meeting & Exposition: Lymphoma

Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.

Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.

Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.

Results from the CLOVER WaM trial saw a clinical benefit rate of 98.2% in patients with Waldenström Macroglobulinemia treated with Iopofosine I 131.

Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

Autologous transplant did not confer significantly improved overall survival regardless of induction intensity in a phase 3 trial.

Long-term ORR, DOR, PFS, and OS data from the phase 2 Zuma-5 trial supports the use of axi-cel use in relapsed/refractory indolent Non-Hodgkin lymphoma treatment.

Regardless of high-risk features, brexucabtagene autoleucel demonstrated positive and durable responses in BTK-naive MCL.

Glofitamab with polatuzumab vedotin benefited patients with high-grade B-cell lymphomas and who failed prior CAR T-cell therapy.

Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.

Findings from the phase 1/2 CaDAnCe-101 trial showed that promising ORRs in R/R WM and R/R CLL/SLL stemmed from BGB-16673 treatment.

For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.

Tisagenlecleucel shows high rates of MRD-negative status among patients with relapsed/refractory follicular lymphoma in the ELARA trial.

Almost a 100% complete response rate was noted with Zilovertamab Vedotin/R-CHP for patients with DLBCL.

For patients with relapsed/refractory large B-cell lymphoma, PFS and OS data from CD-19-directed, 4-1BB CAR T-cell Liso-cel therapy were consistent with prior results.

For patients with relapsed or refractory diffuse large B-cell lymphoma in the US, tafasitamab elicited promising real-world efficacy outcomes.

For patients with relapsed/refractory diffuse large b-cell lymphoma, meaningful efficacy outcomes were shown with FS118.

DZD8586 results in favorable safety with limited grade 3 or greater treatment-emergent adverse effects in those with B-cell non-Hodgkin lymphoma, according to data from 2 ongoing phase 1 trials.

The phase 2 LuminICE study shows potential for the AFM13/AB-101 combination in treating patients with relapsed or refractory CD30-positive lymphoma.

Treatment with pirtobrutinib may be a standard of care in patients with relapsed/refractory mantle cell lymphoma previously treated with a covalent BTK inhibitor, says Jonathon B. Cohen, MD, MS.

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of axicabtagene ciloleucel for patients with high-risk large B-cell lymphoma.

Zanubrutinib plus obinutuzumab and venetoclax appears to be well tolerated in patients with TP53-mutated mantle cell lymphoma, says Anita Kumar, MD.

The addition of venetoclax to ibrutinib yields a favorable benefit/risk profile in patients with relapsed/refractory MCL, according to data from the phase 3 SYMPATICO trial.

A first-in-human phase 1a/1b trial will evaluate the dose escalation of NX-1607 in patients with persistent lymphoma, including those with diffuse large B-cell lymphoma.

Pirtobrutinib may be a clinically meaningful option for those with relapsed/refractory follicular lymphoma, although additional data are necessary, says Nirav N. Shah, MD.

Investigators report no new safety signals in patients with relapsed/refractory follicular lymphoma following treatment with tisagenlecleucel infusion.

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine appears to be well tolerated in patients with advanced stage classical Hodgkin lymphoma, according to data from the phase 2 SGN35-027 trial.

Auto-HCT results in higher overall survival compared with CAR-T cell therapy in patients with relapsed large B-cell lymphoma while they are in complete response, according to findings from a retrospective study.

Treatment with golidocitinib meets the primary endpoint of ORR as well as the secondary endpoints of PFS and safety in the phase 2 JACKPOT8 trial.